-
Mashup Score: 13
Proposed acquisition adds Nimble’s lead asset, an investigational oral peptide IL23R inhibitor in preclinical development for psoriasis, and a pipeline of other novel oral peptide assets across…
Source: news.abbvie.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 3Oncology Research & Treatment - 14 day(s) ago
AbbVie advances cancer research and treatment to elevate the standard of care for blood cancer patients, and in the future other cancers like solid tumors.
Source: www.abbvie.comCategories: General Medicine News, PayerTweet-
Patients with follicular #lymphoma often relapse or become refractory after initial therapy, and people in this setting face limited treatment options with few readily available medicines. Learn how we’re working to expand treatment options: https://t.co/1eArOLapRN https://t.co/jPWZgypuGN
-
-
Mashup Score: 0Can we find cures faster? - 14 day(s) ago
Learn how AbbVie researchers find and advance ideas that have the potential to cure.
Source: www.abbvie.comCategories: General Medicine News, PayerTweet-
What does curing a disease look like? The short answer: it varies. See what our #researchers look for on the pathway to a #cure: https://t.co/loYsNugO3s https://t.co/g0OLKFxlzm
-
-
Mashup Score: 8AbbVie Completes Acquisition of Aliada Therapeutics - 14 day(s) ago
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer’s disease, ALIA-1758, and novel blood-brain barrier (BBB)-crossing technology to strengthen neuroscience pipeline…
Source: news.abbvie.comCategories: General Medicine News, PayerTweet-
NEWS: @aliadatx is now part of AbbVie. This #acquisition expands our neuroscience pipeline with an investigational therapy in #Alzheimers disease and a novel blood-brain barrier-crossing technology. Read more: https://t.co/A2LWpGAHaL $ABBV https://t.co/2GAIbZ8BQK
-
-
Mashup Score: 8
Data presented at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH) NORTH CHICAGO, Ill., Dec. 9, 2024 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced new…
Source: news.abbvie.comCategories: General Medicine News, PayerTweet-
NEWS: We are presenting new data at #ASH24 evaluating our investigational treatment for diffuse large B-cell #lymphoma patients, in collaboration with @Genmab. Explore: https://t.co/72DgcZdeUj https://t.co/kwF7Rs4iow
-
-
Mashup Score: 4AbbVie Announces Positive Topline Results for the Phase 3 TEMPO-2 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease - 16 day(s) ago
Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-2 flexible-dose monotherapy trial, demonstrating a statistically significant improvement from baseline in the MDS-UPDRS Parts II and…
Source: news.abbvie.comCategories: General Medicine News, PayerTweet-
JUST IN: Today, we announced results from a Phase 3 trial of our investigational #ParkinsonsDisease treatment. Learn more: https://t.co/JrCHyEMXbe https://t.co/fVO4gSBU6A
-
-
Mashup Score: 9
Data presented at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH) NORTH CHICAGO, Ill., Dec. 7, 2024 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced updated…
Source: news.abbvie.comCategories: General Medicine News, PayerTweet-
JUST IN: We’re sharing new data at #ASH24 evaluating our investigational treatment for patients with relapsed or refractory follicular #lymphoma, in collaboration with @Genmab. Read more: https://t.co/FE24Cp2XrQ https://t.co/zKaj1nbrcx
-
-
Mashup Score: 666th ASH Annual Meeting - 19 day(s) ago
You may search for particular presentations by typing key words, an author’s name, or the title in the box below. You may specify the type of search, i.e. whether you want to see pages that contain any or all of the words you specify. The Boolean search option requires one of the keywords and, or, and not, as well as parentheses. The search filters will allow you to restrict your search by date, session type, or abstract category and are all optional. Hold down the Ctrl key while selecting to choose more
Source: ash.confex.comCategories: General Medicine News, PayerTweet-
We’re presenting new data for patients with relapsed/refractory multiple myeloma in an oral presentation at this year’s @ASH_hematology annual meeting, as well as updates from across our #BloodCancer portfolio. Learn more: https://t.co/FEO5o977WY #ASH24 https://t.co/8gOYwUEsOI
-
-
Mashup Score: 4Neuroscience - 19 day(s) ago
AbbVie scientists are focused on how to bring better solutions and therapies to people living with neurological and psychiatric disorders.
Source: www.abbvie.comCategories: General Medicine News, PayerTweet-
This year at #EHC2024, we’re sharing new #migraine data centered around women’s health. This research will help support our understanding of the complexities behind migraine. Learn more about our research interests: https://t.co/Sj4LNuRcHK https://t.co/3N3U1hTnom
-
-
Mashup Score: 4Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine - 20 day(s) ago
Key PointsELN 2017 and 2022 prognostic classifiers did not adequately stratify OS outcomes for patients with AML treated with venetoclax-azacitidine.A 4-ge
Source: ashpublications.orgCategories: General Medicine News, PayerTweet-
Recently published in @BloodJournal and @AjHematology are publications of our phase 3 studies of patients with newly diagnosed acute myeloid leukemia (#AML). Read more: https://t.co/kdTh7akw6u and https://t.co/cL4YmAgXX6 https://t.co/2yRlB788iu
-
JUST IN: We’ve signed a definitive agreement to acquire Nimble Therapeutics to further strengthen our #immunology pipeline, with a goal of developing novel medicines for people living with #autoimmune diseases. Learn more: https://t.co/oeT8ji285B https://t.co/xk6K0E5tWW